JSR Corporation, listed on Tokyo Stock Exchange, recently completed its acquisition of Selexis SA, a pioneering life sciences company and global leader in mammalian cell-line generation technologies.

JSR was represented by Transatlantic Law International (TALI) and VISCHER as the Swiss M&A legal counsel. The VISCHER team was led by Christian Wyss, partner and head of the VISCHER Corporate & Commercial practice team, and included Gian-Andrea Caprez (managing associate, M&A), Marc Prinz (partner, employment) and Nadia Tarolli (partner, tax).

JSR Corporation, through its business unit JSR Life Sciences, provides specialized materials and products to the biotech industry. JSR Life Sciences operates a network of manufacturing facilities, sales offices and R&D labs in key markets throughout North America, Europe and Asia-Pacific.